BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31360080)

  • 1. Waldenström macroglobulinemia: biology, genetics, and therapy.
    Paludo J; Ansell SM
    Blood Lymphat Cancer; 2016; 6():49-58. PubMed ID: 31360080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in the management of Waldenström macroglobulinemia.
    Abeykoon JP; Yanamandra U; Kapoor P
    Cancer Manag Res; 2017; 9():73-83. PubMed ID: 28331368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib for the treatment of Waldenström macroglobulinemia.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
    Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
    Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
    Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
    Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significances of MYD88
    Meng Q; Cao XX; Li J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
    Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
    Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.
    Zanwar S; Abeykoon JP
    Ther Adv Hematol; 2022; 13():20406207221093962. PubMed ID: 35510210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
    Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
    [No Abstract]   [Full Text] [Related]  

  • 14. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
    Xu L; Hunter ZR; Tsakmaklis N; Cao Y; Yang G; Chen J; Liu X; Kanan S; Castillo JJ; Tai YT; Zehnder JL; Brown JR; Carrasco RD; Advani R; Sabile JM; Argyropoulos K; Lia Palomba M; Morra E; Trojani A; Greco A; Tedeschi A; Varettoni M; Arcaini L; Munshi NM; Anderson KC; Treon SP
    Br J Haematol; 2016 Mar; 172(5):735-44. PubMed ID: 26659815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
    Ballester LY; Loghavi S; Kanagal-Shamanna R; Barkoh BA; Lin P; Medeiros LJ; Luthra R; Patel KP
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):395-403.e1. PubMed ID: 27268124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
    Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
    J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
    Castillo JJ; Palomba ML; Advani R; Treon SP
    Ther Adv Hematol; 2016 Aug; 7(4):179-86. PubMed ID: 27493708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.